Skip to main content
Premium Trial:

Request an Annual Quote

Macrogen Licenses Broad Institute CRISPR Technology

NEW YORK (GenomeWeb) – South Korean genomic services provider Macrogen announced today that it has acquired a non-exclusive research tool license to CRISPR-Cas9 technology from the Broad Institute.

Macrogen said that it intends to use the genome-editing technology to build preclinical animal models and for target treatment function analysis to advance precision medicine and gene therapy research and development.

Specific terms of the deal were not disclosed.

The Broad has non-exclusively licensed its CRISPR intellectual property to a number of organizations including ag-bio firms Syngenta, BASF, Monsanto, and Arcadia Biosciences, as well as Editas Medicine and Albany Molecular Research.